Here are 16 key notes from orthopedic and spine device companies in the past week.
Orthofix reported net sales of $111.7 million during the third quarter.
NuVasive reported revenue increased 9.8 percent in the third quarter as the company prepares for a CEO transition.
BoneSmart and Maxx Orthopedics partnered to develop educational initiatives for joint replacement patients.
FundamentalVR partnered with Rochester, Minn.-based Mayo Clinic to jointly develop surgical virtual reality simulation and education products.
Chicago-based Medical Sales College partnered with virtual reality surgical training technology company Osso VR, becoming the first medical device educational institution to offer the technology.
Zimmer Biomet reported that its third quarter net sales increased 1.3 percent year-over-year, hitting $1.8 billion.
Centric Medical, a division of Life Spine, received FDA 510(k) clearance for its Saturn External Fixation System.
Biedermann Motech launched the first injection screw that can be used with its polyaxial locking plate systems at the 2018 Orthopaedic Trauma Association Annual Meeting in Orlando, Oct. 17-20.
Principal investigator Elizaveta Kon, MD, PhD, of Humanitas Orthopedic Center of Milan, Italy, enrolled the 100th patient in CariHeal's Agili-C Investigational Device Exemption pivotal study.
Stryker reported a 7.9 percent sales increase in the third quarter of 2018, hitting $3.2 billion.
Bioventus named Susan M. Stalnecker to its board of managers.
The European Patent Office granted Aurora Spine its first European patent for the Zip.
Life Spine experienced a 124 percent earnings before interest, tax, depreciation and amortization growth rate in the third quarter of 2018 compared to the same period in 2017.
Medtronic received FDA approval for its SynchroMed II myPTM Personal Therapy Manager for chronic pain patients.
Richard Weiner, MD, and Bryan Barnes, MD, performed the first cases using Life Spine's Prolift Post Pack Expandable Interbody System.
Camber Spine has generated $1 million from the Spira-C interbody device within six months of its commercial launch.